1. Home
  2. TTRX vs MSLE Comparison

TTRX vs MSLE Comparison

Compare TTRX & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$5.99

Market Cap

174.9M

Sector

Health Care

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$5.67

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
MSLE
Founded
2015
N/A
Country
United States
Canada
Employees
2
17
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.9M
146.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TTRX
MSLE
Price
$5.99
$5.67
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
58.2K
27.5K
Earning Date
05-31-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$5.50
52 Week High
$6.75
$13.39

Technical Indicators

Market Signals
Indicator
TTRX
MSLE
Relative Strength Index (RSI) 56.63 36.50
Support Level $4.70 N/A
Resistance Level $6.68 $8.59
Average True Range (ATR) 0.56 0.39
MACD -0.06 -0.02
Stochastic Oscillator 53.36 0.00

Price Performance

Historical Comparison
TTRX
MSLE

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: